Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Biol Psychiatry. 2014 Sep 28;77(11):940–950. doi: 10.1016/j.biopsych.2014.09.013

Fig 4. Similar neurochemical actions in the prefrontal cortex (PFC) of a selective norepinephrine reuptake inhibitor (SNRI) and a selective dopamine reuptake inhibitor (SDRI).

Fig 4

Shown are the mean (±SEM) change in extracellular norepinephrine (NE) in the PFC and extracellular dopamine (DA) in the PFC and nucleus accumbens (NAcc) expressed as a percent change from baseline. Data are shown for 30-min samples collected prior to (negative numbers) and following (positive numbers) systemic treatment with either (A) the selective NE inhibitor (SNRI), atomoxetine (3 mg/kg) or (B) the selective DA inhibitor (SDRI), AHN 2005 (10 m/kg). At these doses, these drugs exert cognition-enhancing effects. A: The SNRI elicited similar increases in extracellular levels of both NE and DA (~150% above baseline) while having no effect on DA within the NAcc. B: The SDRI also elicited significant increases in both extracellular DA and NE in the PFC that were comparable in magnitude (~100% above baseline). However, in contrast to the SNRI, the SDRI elicited a relatively large increase in extracellular DA levels in the NAcc (~200% above baseline). Panel A adapted from 49. Panel B adapted from 53. Error bars removed for clarity. *P< 0.05, compared to vehicle-treated animals.